Measuring Metastatic Risk in Breast Cancer
“Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment”
The primary aim of the study is to identify genomic and circulating tumor cell (CTC) markers as biomarkers of response to chemotherapy among patients with invasive breast cancer. The secondary aim of this study is to use genomic and CTC markers to evaluate metastatic risk in breast cancer following primary treatments.
Diagnostic Test - Genomic and CTC Markers
This is a non-interventional study.
Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment